PMGC Holdings Inc.

Nasdaq:ELAB

Pharmaceutical Preparations·VANCOUVER

Summary Financials

Revenue

$766,277

FY 2023

Adj. EBITDA

—

Net Income

-$4.3M

-561.4% margin

FY 2024

EPS (Diluted)

-$0.19

FY 2023

Stock Price

$0.75

+6.8%

2026-03-06

52W Range

$0.68 – $114.38

P/E Ratio

-4.0x

Market Cap

$560,695.173

Cash

$3.3M

FY 2024

Total Debt

—

Net Cash

$3.3M

FY 2023

Enterprise Value

-$2.8M

Debt / EBITDA

—

EV / EBITDA

—

Employees

—

Revenue

$766,277

FY 2023

Adj. EBITDA

—

Net Income

-$4.3M

-561.4% margin

FY 2024

EPS (Diluted)

-$0.19

FY 2023

Stock Price

$0.75

+6.8%

2026-03-06

52W Range

$0.68 – $114.38

P/E Ratio

-4.0x

Market Cap

$560,695.173

Cash

$3.3M

FY 2024

Total Debt

—

Net Cash

$3.3M

FY 2023

Enterprise Value

-$2.8M

Debt / EBITDA

—

EV / EBITDA

—

Employees

—